Professional or Occupational Group – Page 4

Breaking the Silence: Endo’s “I Got Somebody” Campaign Encourages Men to Seek Help for Peyronie’s Disease

3 months ago talkbio0Tagged Awareness, campaign, Endometriosis, Hospital specialist, men 's health, nonsurgical treatment options, Peyronie 's disease, Social stigmata, Urology

Peyronie’s disease, men’s health, Endo, “I Got Somebody” campaign, urology specialists, nonsurgical treatment options, disease awareness, stigma reduction.

FTC Targets Pharmacy Benefit Managers Over Exorbitant Price Hikes on Specialty Generic Drugs

3 months ago talkbio0Tagged Benefit, Financial cost, Health care facility, Hikes, manager, Pharmaceutical Services, Pharmacy Benefit Manager, Prices, specialty generic drugs, United States Federal Trade Commission

FTC, Pharmacy Benefit Managers, PBM, Specialty Generic Drugs, Price Hikes, Healthcare Costs

FTC Report Reveals Big 3 PBMs Made $7.3 Billion from Excessive Markups on Specialty Generic Drugs

3 months ago talkbio0Tagged Benefit, Big 3, FTC report, Health care facility, manager, PBMs, Pharmaceutical Services, Prices, specialty generic drugs

FTC report, Big 3 PBMs, Specialty generic drugs, Price markups, Healthcare costs, Pharmacy benefit managers

Sanofi and Alloy Therapeutics Collaborate on CNS Drug Development Using AntiClastic Antisense Platform

4 months ago talkbio0Tagged Alloys, AntiClastic Antisense Platform, Blood - brain barrier anatomy, Clinical Nurse Specialists, Drug Development, Genetic Medicine, RNA, sanofi

Sanofi, Alloy Therapeutics, AntiClastic Antisense Platform, CNS drug development, blood-brain barrier, RNA therapeutics, genetic medicine

GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand

4 months ago talkbio0Tagged agonists, aspects of adverse effects, Diabetes Mellitus, Non-Insulin-Dependent, Employer, Endorsements, Famous Persons, Financial cost, Glucagon-Like Peptide 1, Health Planning, Long-term Safety, Weight Loss

GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans

Healthcare Sector Winners and Losers in the 2024 Government Funding Bill

4 months ago talkbio0Tagged Government, Health care facility, hospital-at-home programs, Legislation, Medicaid, Medicare, pay, Payments, Physicians, shutdown, Symmetrical dyschromatosis of extremities, Telemedicine

Healthcare funding, government shutdown, telehealth, Medicare payments, Medicaid DSH, hospital-at-home programs, physician pay cuts, healthcare legislation.

Negev Labs Unveils Next-Gen Psychedelic Therapies with Non-Hallucinogenic Neuroplastogens

5 months ago talkbio0Tagged Biotechnology, Builder, Hallucinogens, Laboratory test finding, mental health, Negev, neuroplastogens, non-hallucinogenic, psychedelic therapies

Negev Labs, neuroplastogens, psychedelic therapies, non-hallucinogenic psychedelics, mental health treatments, biotechnology company builder

Biotech Funding Boom: Tasca and Citryll Secure Significant Investments

5 months ago talkbio0Tagged Biotech Fundraising, Citryll, Fierce, Tasca, tracker, venture

Biotech fundraising, venture capital, Tasca, Citryll, Fierce Biotech Fundraising Tracker ’24

Alligator Bioscience Slashes 70% of Workforce Due to Financial Strains

5 months ago talkbio0Tagged Alligators, Biopharma, Bioscience, Capital, constraints, Financial Stress, Industry, Staff

Alligator Bioscience, staff cuts, capital constraints, biopharma industry, financial challenges

Controversial Stanford Professor Jay Bhattacharya Nominated by Trump to Lead NIH Amid Criticism Over Pandemic Views

5 months ago talkbio0Tagged Administration occupational activities, Appointments, Bhattacharya, Controversial, COVID19 (disease), Critic, Jay, NIH Director Nomination, Pandemic Response, Professor, Public Health Research, Stanford University, Transplant Registry Unified Management Program

Jay Bhattacharya, NIH Director Nomination, COVID-19 Pandemic Response Critic, Stanford University Professor, Trump Administration, Public Health Research, Controversial Appointment